STOCK TITAN

Kyntra Bio ends FG-3246 and FG-3180 development

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Kyntra Bio, Inc. (KYNB) reported third-quarter 2026 revenue of $1.762 million, versus $1.076 million a year earlier, and continuing-operations income of $157,000, compared with a $13.146 million loss. Results included a $14.011 million gain on debt restructuring. For the first nine months, revenue was $4.026 million versus $5.163 million, and operating loss was $44.258 million versus $32.383 million.

At September 30, 2026, cash, equivalents, investments and receivables totaled $44.1 million; Kyntra Bio expects those resources to fund operations into 2028. An August amendment cut maximum royalty-agreement payments from $125 million to $65 million. Remaining payments are capped at $15 million, payable from 50% of roxadustat drug product revenue recognized from Astellas in Astellas territories excluding Japan. FG-3246 and FG-3180 development was discontinued after an interim Phase 2 analysis found insufficient efficacy; Kyntra Bio expects over $20 million in operating-expense savings in 2027 and 2028. A pivotal roxadustat Phase 3 trial is planned for the first quarter of 2027, subject to execution of either a strategic partnership or an external capital raise.

3 points · 2 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointMaximum royalty payments were cut from $125 million to $65 million.
  • Major point. Forward-looking: it has not happened yet and may not happen.Program termination is expected to save over $20 million in 2027–2028 expenses.
  • Moderate pointThird-quarter revenue reached $1.762 million, up from $1.076 million a year earlier.

Negative

  • Major pointNine-month operating loss widened to $44.258 million from $32.383 million.
  • Moderate pointNine-month revenue fell to $4.026 million from $5.163 million.
  • Moderate pointFG-3246 and FG-3180 development ended after Phase 2 efficacy results were insufficient.

Filing Explained

The completed royalty amendment brings payments to $50 million, including a $42.6 million accelerated payment; once the remaining $15 million cap is met, the agreement ends and Kyntra Bio retains all subsequent EVRENZO royalties in Astellas territories.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter total revenue $1.762 million Three months ended September 30, 2026; $1.076 million in 2025.
Third-quarter income from continuing operations $157,000 Three months ended September 30, 2026; compared with a $13.146 million loss in 2025.
Gain on debt restructuring $14.011 million Three months ended September 30, 2026.
Nine-month total revenue $4.026 million Nine months ended September 30, 2026; $5.163 million in 2025.
Cash, cash equivalents, investments and accounts receivable $44.1 million As of September 30, 2026.
Maximum aggregate royalty-agreement payments $65 million Reduced from $125 million under the amended agreement.
Remaining royalty-backed payments cap $15 million Under the amended royalty financing agreement.
Expected operating-expense savings Over $20 million Expected in 2027 and 2028 from discontinuing the program.
royalty financing agreement financial
"amendment and restatement of its existing royalty financing agreement"
An agreement where a company receives upfront capital in exchange for paying a fixed percentage of future sales or product royalties until a set amount is repaid. Think of it as selling a slice of future revenue instead of issuing shares or taking a traditional loan; it preserves ownership while creating a predictable payment stream tied to business performance. Investors care because it affects future cash flow, growth funding needs, and the return profile without diluting equity.
HIF-PH inhibitors medical
"a new class of medicines comprising HIF-PH inhibitors"
HIF‑PH inhibitors are a class of drugs that block prolyl hydroxylase enzymes, which stabilizes hypoxia‑inducible factors (HIFs) inside cells and increases production of erythropoietin and other proteins that boost red blood cell production and regulate iron. They matter to investors because clinical trial results, regulatory approvals, manufacturing scale and safety data determine commercial opportunity in treating anemia and related conditions, affecting company revenues and stock performance.
erythropoiesis medical
"promote erythropoiesis, or red blood cell production"
The body's process for making red blood cells in the bone marrow, driven by signals such as a hormone that tells immature cells to mature and enter the bloodstream. Think of it as a factory assembly line that builds the blood’s oxygen delivery trucks; when the line speeds up or breaks down it changes demand for drugs, diagnostics and treatments. Investors watch it because therapies that boost or regulate this process can reshuffle market value in hematology, transfusion services and related drugs.
lower-risk myelodysplastic syndromes medical
"anemia associated with lower-risk myelodysplastic syndromes"
high transfusion burden medical
"patients with LR-MDS and HTB"
A high transfusion burden describes patients who require frequent, regular blood transfusions to manage chronic anemia or blood disorders—often multiple times per month or year. For investors it signals ongoing, predictable medical costs and a clear unmet need: therapies that reduce transfusion frequency can improve patient quality of life, lower long‑term care costs, and become valuable commercial or regulatory differentiators in clinical trials, much like fixing a leaky bucket saves repeated refills.
pre-specified interim analysis medical
"Following a pre-specified interim analysis of the ongoing Phase 2 study"
Total revenue $1.762 million Compared with $1.076 million in the third quarter of 2025.
Income from continuing operations $157,000 Compared with a $13.146 million loss in the third quarter of 2025.
Income from continuing operations per basic and diluted share $0.04 Compared with a $3.25 loss per basic and diluted share in the third quarter of 2025.
Gain on debt restructuring $14.011 million Reported for the third quarter of 2026.
Guidance

Kyntra Bio expects cash, cash equivalents, investments and accounts receivable to fund operating plans into 2028. It plans to initiate the pivotal roxadustat Phase 3 trial in the first quarter of 2027, subject to execution of either a strategic partnership or an external capital raise.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were KYNB's third-quarter 2026 revenue and continuing earnings?

Kyntra Bio reported $1.762 million of total revenue for the third quarter of 2026, versus $1.076 million a year earlier. Income from continuing operations was $157,000, compared with a $13.146 million loss; results included a $14.011 million gain on debt restructuring.

How long does KYNB expect its cash to fund operations?

As of September 30, 2026, Kyntra Bio reported $44.1 million in cash, cash equivalents, investments and accounts receivable. It expects these resources to fund operating plans into 2028.

What are KYNB's remaining royalty-payment terms after its amendment?

The August 2026 amendment reduced maximum aggregate payments from $125 million to $65 million, including a $42.6 million accelerated payment. Remaining payments are capped at $15 million, payable from 50% of roxadustat drug product revenue Kyntra Bio recognizes from Astellas in Astellas territories excluding Japan. After the cap is reached, the agreement terminates and Kyntra Bio retains subsequent EVRENZO royalties in Astellas territories.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0000921299false00009212992026-11-162026-11-16

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

 

 

KYNTRA BIO, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-36740

77-0357827

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

350 Bay Street

Suite 100 #6009

 

San Francisco, California

 

94133

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 415 978-1200

 

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.01 par value

 

KYNB

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


Item 2.02 Results of Operations and Financial Condition.

On November 16, 2026, Kyntra Bio, Inc. (“Kyntra Bio”) issued a press release announcing financial results for the quarter ended September 30, 2026. A copy of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02, in Exhibit 99.1 shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Kyntra Bio, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.

Description

99.1

Press Release dated November 16, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

KYNTRA BIO, INC.

 

 

 

 

Date:

November 16, 2026

By:

/s/ David DeLucia

 

 

 

David DeLucia
Senior Vice President and Chief Financial Officer

 


Exhibit 99.1

Kyntra Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

 

•
Completed restructuring of royalty financing agreement, reducing the maximum aggregate payment obligation by $60 million, with only $15 million in future royalty-backed payments remaining
•
Initiation of the pivotal Phase 3 trial of roxadustat for the treatment of anemia in LR-MDS patients with high transfusion burden (HTB) planned in 1Q 2027, subject to the execution of either a strategic partnership or an external capital raise
•
Decision to discontinue development of FG-3246 and FG-3180 following insufficient efficacy at the pre-specified Phase 2 interim analysis in metastatic castration-resistant prostate cancer (mCRPC), resulting in a reduction of over $20 million in operating expenses in 2027 and 2028
•
Cash, cash equivalents, investments, and accounts receivable of $44.1 million as of September 30, 2026, with a cash runway now into 2028
•
Kyntra Bio to host conference call and webcast presentation today at 5:00 PM ET

 

SAN FRANCISCO, November 16, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the third quarter 2026 and provided an update on the company’s recent developments.

“Following a pre-planned interim analysis showing insufficient efficacy, we have made the decision to terminate the FG-3246 Phase 2 trial,” said Thane Wettig, Chief Executive Officer of Kyntra Bio. “We continue to work towards the completion of our transformation to a pure-play, rare disease company laser-focused on the initiation and execution of the Phase 3 roxadustat trial. The unmet medical need and corresponding multi-billion-dollar commercial opportunity in LR-MDS is significant. Subject to the execution of either a strategic partnership or an external capital raise, we plan on initiating the pivotal Phase 3 trial in the first quarter of 2027.”

 

Key Highlights of Third Quarter, Recent Developments, and Upcoming Milestones

Roxadustat

•
Initiation of the pivotal Phase 3 trial of roxadustat for the treatment of anemia in patients with LR-MDS and HTB planned in the first quarter of 2027, subject to the execution of either a strategic partnership or an external capital raise.

 

FG-3246 (CD46 Targeting ADC) and FG-3180 (CD46 Targeting PET Imaging Agent)

•
Following a pre-specified interim analysis of the ongoing Phase 2 study of FG-3246 in mCRPC, the Company decided to close enrollment in the study and discontinue development of the program.
o
Preliminary efficacy results at the interim analysis did not meet the threshold required to support continued development.
•
The Company plans to complete the close-out of the study over the coming months and will cancel all planned future investment in the program.
•
The Company expects to save over $20 million in operating expenses in 2027 and 2028 from the termination of the study.

 

 

 

 

 

 

 

 

 

 


Corporate

•
In August 2026, the company signed an amendment and restatement of its existing royalty financing agreement with NQ Project Phoebus, L.P., materially reducing its payment obligations under the agreement in exchange for an accelerated upfront payment. The amendment included the following terms:
o
Reduction of the maximum aggregate payments under the agreement from $125 million to $65 million, including the $42.6 million accelerated payment to NQ Project Phoebus, L.P., bringing total payments made to date to $50 million, a full return of NQ Project Phoebus, L.P.’s invested capital.
o
Remaining payments, capped at $15 million, to be paid from 50% of the roxadustat drug product revenue Kyntra Bio recognizes from Astellas in the Astellas territories excluding Japan.
o
Once the $15 million cap is reached, the amended agreement will terminate, with Kyntra Bio retaining all subsequent EVRENZO™ royalties in the Astellas territories.
•
Appointed Andrew E. Singer, MBA to the Board of Directors.

 

 

Financial

•
Total revenue from continuing operations for the third quarter of 2026 was $1.8 million, as compared to $1.1 million for the third quarter of 2025.
•
Net income from continuing operations for the third quarter of 2026 was $0.2 million, or $0.04 net income per basic and diluted share, compared to a net loss of $13.1 million, or $3.25 net loss per basic and diluted share, one year ago.
•
As of September 30, 2026, Kyntra Bio reported $44.1 million in cash, cash equivalents, investments, and accounts receivable.
•
The Company expects its cash, cash equivalents, investments, and accounts receivable to be sufficient to fund operating plans into 2028.

 

Conference Call and Webcast Presentation

Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on Kyntra Bio’s website.

 

About Roxadustat

Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin.

 

Roxadustat is approved in Europe, Japan, China, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD). Kyntra Bio has the sole rights to roxadustat in the United States, Canada, Mexico, and in all markets not held by AstraZeneca or licensed to Astellas. Astellas and Kyntra Bio are collaborating on the commercialization of roxadustat for the treatment of anemia in territories including Japan, Europe, Turkey, Russia, and the Commonwealth of Independent States, the Middle East, and South Africa.

 

Following promising results from the Phase 2/3 MATTERHORN study, the Company is planning to study roxadustat in a pivotal Phase 3 trial in patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden (HTB).

 

About Kyntra Bio

Kyntra Bio is a pure play, rare disease biopharmaceutical company focused on the development of roxadustat for anemia associated with lower-risk myelodysplastic syndromes (LR-MDS). Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company is planning to study roxadustat in a pivotal Phase 3 trial in patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS). For more information, please visit www.kyntrabio.com.


 

Forward-Looking Statements

This release contains forward-looking statements regarding Kyntra Bio’s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its partners Fortis and UCSF. These forward-looking statements include, but are not limited to, statements regarding the efficacy, safety, and potential clinical or commercial success of Kyntra Bio products and product candidates, statements under the caption “Recent Highlights and Upcoming Milestones”, statements about regulatory interactions, statements regarding cash, such as the expectation that cash, cash equivalents and accounts receivable will be sufficient to fund Kyntra Bio’s operating plans into 2028, and statements about Kyntra Bio’s plans and objectives. These forward-looking statements are typically identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. Kyntra Bio’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in Kyntra Bio’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Kyntra Bio undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

# # #

 


Condensed Consolidated Balance Sheets

(In thousands)

 

 

September 30, 2026

 

 

December 31, 2025

 

 

(Unaudited)

 

 

(1)

 

Assets

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

$

9,905

 

 

$

47,872

 

Short-term investments

 

30,385

 

 

 

41,106

 

Accounts receivable, net

 

3,848

 

 

 

216

 

Inventory

 

3,255

 

 

 

3,743

 

Prepaid expenses and other current assets

 

1,227

 

 

 

6,136

 

Total current assets

 

48,620

 

 

 

99,073

 

Long-term investments

 

—

 

 

 

20,160

 

Other assets

 

231

 

 

 

361

 

Total assets

$

48,851

 

 

$

119,594

 

 

 

 

 

 

 

Liabilities, stockholders’ equity and non-controlling interests

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Accounts payable

$

4,581

 

 

$

3,745

 

Accrued and other liabilities

 

31,005

 

 

 

20,183

 

Deferred revenue

 

6,170

 

 

 

5,314

 

Total current liabilities

 

41,756

 

 

 

29,242

 

Product development obligations

 

—

 

 

 

19,560

 

Deferred revenue, net of current

 

2,957

 

 

 

255

 

Liability related to sale of future revenues, non-current

 

11,268

 

 

 

65,980

 

Other long-term liabilities

 

60

 

 

 

82

 

Total liabilities

 

56,041

 

 

 

115,119

 

 

 

 

 

 

 

Redeemable non-controlling interests

 

21,480

 

 

 

21,480

 

Total stockholders’ deficit attributable to Kyntra Bio

 

(29,190

)

 

 

(30,038

)

Nonredeemable non-controlling interests

 

520

 

 

 

13,033

 

Total deficit

 

(28,670

)

 

 

(17,005

)

Total liabilities, redeemable non-controlling interests and deficit

$

48,851

 

 

$

119,594

 

 

(1)
The condensed consolidated balance sheet amounts at December 31, 2025 are derived from audited financial statements.

 


Condensed Consolidated Statements of Operations

(In thousands, except per share data)

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

(Unaudited)

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

Development and other revenue

$

99

 

 

$

119

 

 

 

449

 

 

 

396

 

Drug product revenue, net

 

1,663

 

 

 

957

 

 

 

3,577

 

 

 

4,767

 

Total revenue

 

1,762

 

 

 

1,076

 

 

 

4,026

 

 

 

5,163

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

619

 

 

 

(58

)

 

 

4,727

 

 

 

278

 

Research and development

 

8,266

 

 

 

1,209

 

 

 

22,654

 

 

 

16,249

 

Selling, general and administrative

 

5,757

 

 

 

5,295

 

 

 

20,951

 

 

 

20,459

 

Restructuring charge

 

(15

)

 

 

41

 

 

 

(48

)

 

 

560

 

Total operating costs and expenses

 

14,627

 

 

 

6,487

 

 

 

48,284

 

 

 

37,546

 

Loss from operations

 

(12,865

)

 

 

(5,411

)

 

 

(44,258

)

 

 

(32,383

)

 

 

 

 

 

 

 

 

 

 

 

 

Interest and other, net:

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

(1,632

)

 

 

(2,083

)

 

 

(6,426

)

 

 

(6,346

)

Gain on deconsolidation of subsidiary

 

—

 

 

 

—

 

 

 

30,940

 

 

 

—

 

Loss on debt extinguishments

 

—

 

 

 

(6,583

)

 

 

—

 

 

 

(6,583

)

Gain on debt restructuring

 

14,011

 

 

 

—

 

 

 

14,011

 

 

 

—

 

Interest income and other income (expenses), net

 

643

 

 

 

931

 

 

 

2,731

 

 

 

1,628

 

Total interest and other, net

 

13,022

 

 

 

(7,735

)

 

 

41,256

 

 

 

(11,301

)

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from continuing operations before income taxes

 

157

 

 

 

(13,146

)

 

 

(3,002

)

 

 

(43,684

)

Benefit from income taxes

 

—

 

 

 

—

 

 

 

(1

)

 

 

(90

)

Income (loss) from continuing operations

 

157

 

 

 

(13,146

)

 

 

(3,001

)

 

 

(43,594

)

Income (loss) from discontinued operations, net of tax

 

—

 

 

 

213,782

 

 

 

(66

)

 

 

241,266

 

Net income (loss)

$

157

 

 

$

200,636

 

 

$

(3,067

)

 

$

197,672

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from continuing operations per share - basic
    and diluted

$

0.04

 

 

$

(3.25

)

 

$

(0.74

)

 

$

(10.79

)

Income (loss) from discontinued operations per share - basic
    and diluted

 

—

 

 

 

52.86

 

 

 

(0.02

)

 

 

59.69

 

Net income (loss) per share - basic and diluted

$

0.04

 

 

$

49.61

 

 

$

(0.76

)

 

$

48.90

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares used to
    calculate net income (loss) per share:

 

 

 

 

 

 

 

 

 

 

 

Basic

 

4,049

 

 

 

4,044

 

 

 

4,048

 

 

 

4,042

 

Diluted

 

4,050

 

 

 

4,044

 

 

 

4,048

 

 

 

4,042

 

 

# # #

 

For Investor Inquiries:

David DeLucia, CFA

Senior Vice President and Chief Financial Officer

ir@kyntrabio.com

 


Filing Exhibits & Attachments

2 documents

Keep reading